Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 1/20 | 0.54 |
| ▸ | ESR1 | P03372 | 6/20 | 0.52 |
| ▸ | ESR2 | Q92731 | 6/20 | 0.52 |
| ▸ | CA12 | O43570 | 3/20 | 0.49 |
| ▸ | CA1 | P00915 | 3/20 | 0.49 |
| ▸ | CA2 | P00918 | 3/20 | 0.49 |
| ▸ | CA3 | P07451 | 3/20 | 0.49 |
| ▸ | CA4 | P22748 | 3/20 | 0.49 |
| ▸ | CA6 | P23280 | 3/20 | 0.49 |
| ▸ | CA7 | P43166 | 3/20 | 0.49 |
| ▸ | CA9 | Q16790 | 3/20 | 0.49 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.49 |
| ▸ | CA13 | Q8N1Q1 | 2/20 | 0.49 |
| ▸ | CA5A | P35218 | 2/20 | 0.47 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.46 |
| ▸ | HTR2C | P28335 | 1/20 | 0.46 |
| ▸ | HTR7 | P34969 | 1/20 | 0.46 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.46 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.46 |
| ▸ | HTR6 | P50406 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6342287 | 0.82 | ESR2 (0.68) | ESR1ESR2 | |
| SCHEMBL16370353 | 0.80 | ADORA2A (0.52) | ADORA2AESR1ESR2 | |
| SCHEMBL12084444 | 0.80 | KCNH3 (0.59) | ADORA2ACA12CA1CA2CA9 | |
| SCHEMBL6337738 | 0.79 | ESR1 (0.43) | ADORA2AESR1ESR2 | |
| SCHEMBL6344145 | 0.77 | ESR1 (0.51) | ESR1ESR2CA12CA1CA2 | |
| SCHEMBL6336679 | 0.77 | CA12 (0.50) | CA12CA1CA2CA4CA6 | |
| SCHEMBL12084439 | 0.76 | CA9 (0.55) | ADORA2ACA9KCNH3 | |
| SCHEMBL13421016 | 0.72 | KCNH3 (0.66) | ESR1ESR2KCNH3 | |
| SCHEMBL12084453 | 0.72 | FCGR3B (0.49) | ADORA2AESR1ESR2KCNH3 | |
| SCHEMBL13718623 | 0.72 | ADORA2A (0.46) | ADORA2AESR1ESR2CA12CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6943162-B2 | Osteoporosis; cardiovascular disorders; anticancer agents;incontinence | SMITHKLINE BEECHAM CORPORATION (US) | 2005-09-13 | — | — | US | disclosed |
| US-20040072829-A1 | Piperazinyltriazines as estrogen receptor modulators | SMITHKLINE BEECHAM CORPORATION | 2004-04-15 | — | — | US | disclosed |
| WO-2002072561-A1 | PIPERAZINYLTRIAZINES AS ESTROGEN RECEPTOR MODULATORS | SMITHKLINE BEECHAM CORPORATION (US) | 2002-09-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040072829-A1 | Piperazinyltriazines as estrogen receptor modulators | GPER1, ESR2, ESR1 | ADORA2A 333/4885ESR1 3/4885ESR2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.